Copyright
©The Author(s) 2021.
World J Clin Cases. Jan 6, 2021; 9(1): 71-80
Published online Jan 6, 2021. doi: 10.12998/wjcc.v9.i1.71
Published online Jan 6, 2021. doi: 10.12998/wjcc.v9.i1.71
Patient | Age/gender | Histological type of thyroid cancer | Stage of thyroid cancer | Histological type of lung cancer | Tumor size of lung cancer | Stage of lung cancer | Interval between thyroid cancer and lung cancer diagnosis | Indication and dose of 131I | Interval between 131I administration and lung cancer histological confirmation | 131I uptake in lung cancer | NIS expression in lung cancer (staining intensity/percentage) |
1 | 50/F | Papillary | T1aN0bM0 | Adenocarcinoma | 1.7 cm | T1bN0M0 | 1.5 yr | Elevated Tg antibody level/30 mCi | 5.7 mo | Positive | Weak/60% |
2 | 50/F | Papillary | T1bN0bM0 | Adenocarcinoma | 2.5 cm | T1bN1M0 | 15.3 yr | Thyroid remnant ablation/30 mCi | 11.3 mo | Negative | Weak/15% |
3 | 47/M | Papillary | T2N1aM0 | Adenocarcinoma | 2.4 cm | T2aN0M1a | 0.2 yr | Elevated Tg level/100 mCi | 1.2 mo | Negative | Weak/10% |
4 | 44/F | Papillary | TxN0bM0 | Adenocarcinoma | 3.2 cm | T4N3M0 | 18.4 yr | Neck sonography suggesting tumor recurrence/200 mCi | 1.8 mo | Negative | Negative |
5 | 66/F | Papillary | TxN0bM0 | Adenocarcinoma | 2.4 cm | T2aN1M0 | 10.2 yr | Thyroid cancer surveillance/2 mCi | 1.7 mo | Negative | Negative |
6 | 67/M | Papillary | T1bN1bM0 | Adenocarcinoma | 3.8 cm | T4N2M0 | 3.0 yr | Elevated Tg level/200 mCi | 3.1 mo | Negative | Negative |
7 | 55/F | Papillary | T2N1bM0 | Adenocarcinoma | 3.0 cm | T1cN0M0 | 0.3 yr | Thyroid remnant ablation/30 mCi | 0.8 mo | Negative | Negative |
8 | 56/F | Papillary | T3aN1aM1 | Adenocarcinoma | 1.8 cm | T2aN2M0 | 7.6 yr | Elevated Tg level/100 mCi | 3.1 mo | Negative | – |
9 | 69/M | Papillary | T1aN0bM0 | Non-small cell lung carcinoma-not otherwise specified | 4.3 cm | T2bN2M0 | 1.0 yr | Elevated Tg level/30 mCi | 6.5 mo | Negative | Negative |
Case | Author/year | Age/gender | Histological type of thyroid cancer | Dose of 131I | Histological type of lung cancer |
1 | Fernandez-Ulloa et al[21]/ 1976 | 54/M | No primary thyroid cancer identified | Not reported | Adenocarcinoma |
2 | Acosta et al[22]/1982 | 57/F | No primary thyroid cancer identified | Not reported | Large cell undifferentiated carcinoma |
3 | Langsteger et al[23]/1990 | 64/M | Papillary thyroid cancer | 5 mCi | Moderately-differentiated tubular adenocarcinoma |
4 | Haubold-Reuter et al[24]/ 1993 | Not reported | Papillary thyroid cancer | 20 mCi | Small to medium cell undifferentiated bronchial carcinoma |
5 | Misaki et al[25]/1994 | 71/M | Papillary thyroid cancer | 120 mCi | Squamous cell carcinoma |
6 | Malhotra et al[26]/2008 | 52/M | Follicular thyroid cancer | 182 mCi | Mucinous bronchoalveolar carcinoma |
- Citation: Lu YL, Chen ST, Ho TY, Chan WH, Wong RJ, Hsueh C, Lin SF. Primary lung cancer with radioiodine avidity: A thyroid cancer cohort study. World J Clin Cases 2021; 9(1): 71-80
- URL: https://www.wjgnet.com/2307-8960/full/v9/i1/71.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v9.i1.71